VFA
BCLI

Valeo Financial Advisors’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Valeo Financial Advisors’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-97
Closed -$6K – 650
2021
Q1 		$6K Hold
97
– – ﹤0.01% 1494
2020
Q4 		$7K Hold
97
– – ﹤0.01% 1271
2020
Q3 		$25K Hold
97
– – ﹤0.01% 862
2020
Q2 		$16K Buy
97
+60
+162% +$6.47K ﹤0.01% 1129
2020
Q1 		$3K Hold
37
– – ﹤0.01% 1398
2019
Q4 		$2K Hold
37
– – ﹤0.01% 1437
2019
Q3 		$2K Hold
37
– – ﹤0.01% 1362
2019
Q2 		$2K Hold
37
– – ﹤0.01% 1380
2019
Q1 		$2K Buy
+37
New +$2.1K ﹤0.01% 1333

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
AHB
Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Valeo Financial Advisors's BCLI Position: Q2 2021 in Review

Valeo Financial Advisors sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q2 2021, closing a stake of 97 shares — an estimated $6K sold.

Valeo Financial Advisors first reported a position in BCLI in Q1 2019 and held it in 9 quarters. The position peaked at $25K in Q3 2020. 57 funds tracked by Wall St. Rank hold BCLI as of Q2 2021.

  • Valeo Financial Advisors reported no remaining BRAINSTORM CELL THERAPUTC position as of Q2 2021 after selling out during the quarter.
  • Valeo Financial Advisors sold 97 BRAINSTORM CELL THERAPUTC shares in Q2 2021, an estimated $6K.
  • Valeo Financial Advisors first reported a position in BRAINSTORM CELL THERAPUTC in Q1 2019 and held it in 9 quarters.
  • Valeo Financial Advisors's BRAINSTORM CELL THERAPUTC position peaked at $25K in Q3 2020.
  • 57 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q2 2021.

Based on Valeo Financial Advisors's 13F filing for Q2 2021, filed 22 Jul 2021.